Cargando…
Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19
The emergence of the COVID-19 pandemic has led to significant uncertainty among physicians and patients about the safety of immunosuppressive medications used for the management of dermatologic conditions. We review available data on commonly used immunosuppressants and their effect on viral infecti...
Autores principales: | Galimberti, Fabrizio, McBride, Jeffrey, Cronin, Megan, Li, Yumeng, Fox, Joshua, Abrouk, Michael, Herbst, Alexander, Kirsner, Robert S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224642/ https://www.ncbi.nlm.nih.gov/pubmed/32419721 http://dx.doi.org/10.1016/j.clindermatol.2020.05.003 |
Ejemplares similares
-
Immunosuppressive and immunomodulatory therapies in dermatology and coronavirus disease 2019 (COVID-19)
por: Mansouri, Parvin, et al.
Publicado: (2021) -
The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy
por: Gualdi, Giulio, et al.
Publicado: (2021) -
Dermatologic reactions to disinfectant use during the COVID-19 pandemic
por: Goh, Choon Fu, et al.
Publicado: (2021) -
Addendum to: Eruption as a clinical manifestation of COVID-19: Photographs of a patient
por: Hoenig, Leonard J., et al.
Publicado: (2021) -
Paraviral eruptions in the era of COVID-19: Do some skin manifestations point to a natural resistance to SARS-CoV-2?
por: Lipsker, Dan
Publicado: (2020)